Beacon Topco, Inc. filed a Form 10-Q for the quarterly period ended September 30, 2026, reporting condensed consolidated financial results for the three and nine months ended on that date.
Key Highlights
- Quarterly net loss: Net loss attributable to Beacon Topco, Inc. shareholders was $6,104 thousand for the three months ended September 30, 2026, compared with $14,566 thousand in the same period of 2025, according to the filing.
- Nine-month net loss: For the nine months ended September 30, 2026, net loss attributable to shareholders was $22,215 thousand, versus $55,338 thousand in the prior-year period, the filing disclosed.
- Total assets: The company reported total assets of $70,799 thousand as of September 30, 2026, down from $98,169 thousand as of December 31, 2025.
- Cash position: Cash and cash equivalents stood at $49,241 thousand at September 30, 2026, compared with $70,456 thousand at December 31, 2025.
- Shares outstanding: As of November 12, 2026, the registrant had 3,618,160 shares of common stock, par value $0.0001 per share, outstanding.
- Planned name change: The filing states the registrant plans to change its name to "Clywedog Therapeutics Holdings, Inc." following the completion of a transaction described in the filing.
- Share premium reallocation: During Q3 2026, the company recorded a share premium reallocation of $(103,220) thousand within additional paid-in capital, offset against accumulated deficit, the filing shows.
Beacon Topco Reports Reduced Operating Expenses and Declining Cash in Third Quarter 2026
Beacon Topco, Inc., a Delaware-incorporated company headquartered at 20400 Century Blvd, Suite 210, Germantown, MD 20874, is engaged in therapeutics development and operates as a smaller reporting company and emerging growth company under SEC definitions, as indicated on the filing's cover page. The company's securities registered under Section 12(b) are listed as "None," with trading symbol and exchange both shown as "N/A" on the filing's cover page.
According to the filing, total operating expenses for the three months ended September 30, 2026, were $6,464 thousand, compared with $15,222 thousand in the same quarter of 2025. Research and development expenses declined to $1,324 thousand from $5,390 thousand year-over-year for the quarter, while general and administrative expenses were $5,140 thousand versus $5,165 thousand. For the nine months ended September 30, 2026, total operating expenses were $23,609 thousand, compared with $59,488 thousand in the nine months ended September 30, 2025, which included $4,667 thousand in impairment of long-lived assets not present in 2026.
The company's loss from operations for the three-month period was $(6,461) thousand, and for the nine-month period was $(23,555) thousand, the filing reported. Total stockholders' equity attributable to Beacon Topco, Inc. shareholders was $50,840 thousand at September 30, 2026, down from $74,208 thousand at December 31, 2025. The accumulated deficit as of September 30, 2026, was $(223,092) thousand, following a share premium reallocation of $(103,220) thousand that reduced additional paid-in capital and reduced the accumulated deficit by an equal amount in Q3 2026, per the statements of changes in stockholders' equity. The company is authorized to issue 21,000,000 shares of common stock, with 4,538,765 shares issued and outstanding as of September 30, 2026.
What Was Disclosed
Beacon Topco, Inc. filed a quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated balance sheets, statements of operations, changes in stockholders' equity, and cash flows. The filing also notes a planned corporate name change to Clywedog Therapeutics Holdings, Inc. upon completion of a described transaction.





Please wait processing your request...